Financial reports
10-K
2023 FY
Annual report
12 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
Current reports
8-K
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
21 Feb 24
8-K
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
18 Jan 24
8-K
Results of Operations and Financial Condition
9 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
11 Oct 23
8-K
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
7 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
15 May 23
8-K
Regulation FD Disclosure
17 Apr 23
8-K
Ikena Oncology Appoints Owen Hughes as Board Chair
19 Dec 22
Registration and prospectus
S-8
Registration of securities for employees
12 Mar 24
424B5
Prospectus supplement for primary offering
12 Sep 23
D
$42.57 mm in equity, sold $42.57 mm, 48 investors
18 Aug 23
S-3
Shelf registration
18 Aug 23
424B5
Prospectus supplement for primary offering
15 May 23
S-8
Registration of securities for employees
14 Mar 23
S-3
Shelf registration
27 Apr 22
S-8
Registration of securities for employees
17 Mar 22
S-8
Registration of securities for employees
30 Mar 21
424B4
Prospectus supplement with pricing info
26 Mar 21
Other
EFFECT
Notice of effectiveness
11 Sep 23
CORRESP
Correspondence with SEC
6 Sep 23
EFFECT
Notice of effectiveness
6 May 22
CORRESP
Correspondence with SEC
3 May 22
UPLOAD
Letter from SEC
2 May 22
EFFECT
Notice of effectiveness
26 Mar 21
CERT
Certification of approval for exchange listing
25 Mar 21
SEC STAFF
SEC staff action: Order
25 Mar 21
CORRESP
Correspondence with SEC
23 Mar 21
CORRESP
Correspondence with SEC
23 Mar 21
Ownership
SC 13G/A
FMR LLC
11 Mar 24
4
Caroline Germa
5 Mar 24
3
Caroline Germa
5 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Omega Fund VI, L.P.
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Jeffrey Ecsedy
2 Feb 24
4
Jotin Marango
2 Feb 24
4
Mark Manfredi
2 Feb 24